<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04838067</url>
  </required_header>
  <id_info>
    <org_study_id>VC18DNSI0145</org_study_id>
    <nct_id>NCT04838067</nct_id>
  </id_info>
  <brief_title>Validation of Therapeutic Effects of Cefaly on Insomnia</brief_title>
  <official_title>Validation of Therapeutic Effects of Cefaly on Insomnia by Neuroimaging and Polysomnography Analyses: a Single Site, Single-armed Exploratory Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Saint Vincent's Hospital, Korea</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Saint Vincent's Hospital, Korea</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to examine whether the Cefaly has a therapeutic effect on insomnia patients&#xD;
      visiting a psychiatric clinic in Korea. The study design is a single site, single-armed&#xD;
      exploratory study. Insomnia patients received a 20-minute daily sessions of the Cefaly for 4&#xD;
      weeks. Primary endpoint was a reduction of scores in Pittsburgh Sleep Quality Index, Insomnia&#xD;
      Severity Index, Epworth Sleepiness Scale, improvements in polysomnography measures, and&#xD;
      changes in resting state networks, cortical thickness, fractional anisotropy and mean&#xD;
      diffusivity&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Insomnia is well-known for its association with adverse health outcomes. Although insomnia is&#xD;
      usually treated with hypnotics or cognitive behavioral therapy for insomnia, the need for&#xD;
      novel nonpharmacological treatment for insomnia is increasing emphasized due to reports of&#xD;
      side effects and detrimental consequences of hypnotics. Trigeminal nerve electrical&#xD;
      neuromodulation has been suggested as a potential treatment modality through its modulation&#xD;
      of noradrenergic activity that results in promoting relaxation and reducing hyperarousal.&#xD;
      Insomnia patients enrolled in the study will go through a 20-minute daily session of the&#xD;
      Cefaly device(originally FDA-approved device for migraine, which electrically modulates&#xD;
      trigeminal nerve) for 4 weeks. The objective of this study is to test whether trigeminal&#xD;
      nerve electrical neuromodulation has a therapeutic effect, validation measures involving&#xD;
      subjective measures(Pittsburgh Sleep Quality Index, Insomnia Severity Index, Epworth&#xD;
      Sleepiness Scale), objective measures(Polysomnography measures) and neuroimaging(changes in&#xD;
      resting state networks, cortical thickness, fractional anisotropy and mean diffusivity).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 26, 2018</start_date>
  <completion_date type="Actual">July 14, 2020</completion_date>
  <primary_completion_date type="Actual">April 7, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pittsburgh sleep quality index(PSQI)</measure>
    <time_frame>4 weeks after intervention</time_frame>
    <description>Changes in Pittsburgh sleep quality index scores PSQI global score of more than 5 signifies major sleep disturbance, higher scores suggesting greater sleep disturbance.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Insomnia severity index(ISI)</measure>
    <time_frame>4 weeks after intervention</time_frame>
    <description>Changes in Insomnia severity index scores ISI is a brief, self-rated scale that is widely used to measure insomnia severity. With seven items scored on a 0-4 scale, it only takes about 5 minutes to complete and scores of 15 or more indicates insomnia of moderate to severe severity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Epworth sleepiness scale(ESS)</measure>
    <time_frame>4 weeks after intervention</time_frame>
    <description>Changes in Epworth sleepiness scale scores Score of more than 10 signifies clinically meaningful daytime sleepiness, with higher scores indicating more severe sleepiness.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Polysomnography measures-1 (Total sleep time)</measure>
    <time_frame>4 weeks after intervention</time_frame>
    <description>Changes in Total sleep time</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Polysomnography measures-2 (Wake after sleep onset)</measure>
    <time_frame>4 weeks after intervention</time_frame>
    <description>Changes in Wake after sleep onset</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Polysomnography measures-3( Stage 1 sleep period)</measure>
    <time_frame>4 weeks after intervention</time_frame>
    <description>Changes in Stage 1 sleep period</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Polysomnography measures-4(Stage 2 sleep period)</measure>
    <time_frame>4 weeks after intervention</time_frame>
    <description>Changes in Stage 2 sleep period</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Polysomnography measures-5(Stage 3 sleep period)</measure>
    <time_frame>4 weeks after intervention</time_frame>
    <description>Changes in Stage 3 sleep period</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Polysomnography measures-6(Total rapid eye movement sleep period)</measure>
    <time_frame>4 weeks after intervention</time_frame>
    <description>Changes in Total rapid eye movement sleep period</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Polysomnography measures-7(Rapid eye movement sleep latency)</measure>
    <time_frame>4 weeks after intervention</time_frame>
    <description>Changes in Rapid eye movement sleep latency</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Polysomnography measures-8(Sleep latency)</measure>
    <time_frame>4 weeks after intervention</time_frame>
    <description>Changes in Sleep latency</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Polysomnography measures-9(Apnea hypopnea index)</measure>
    <time_frame>4 weeks after intervention</time_frame>
    <description>Changes in Apnea hypopnea index</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Neuroimaging parameter changes-1(Resting state network functional connectivity)</measure>
    <time_frame>4 weeks after intervention</time_frame>
    <description>Resting state network functional connectivity changes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Neuroimaging parameter changes-2(Cortical thickness)</measure>
    <time_frame>4 weeks after intervention</time_frame>
    <description>Changes in Cortical thickness</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Neuroimaging parameter changes-4(Fractional anisotropy)</measure>
    <time_frame>4 weeks after intervention</time_frame>
    <description>Changes in Fractional anisotropy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Neuroimaging parameter changes-5(Mean diffusivity)</measure>
    <time_frame>4 weeks after intervention</time_frame>
    <description>Changes in Mean diffusivity</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Sleep Initiation and Maintenance Disorders</condition>
  <arm_group>
    <arm_group_label>Cefaly Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cefaly</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cefaly</intervention_name>
    <description>Transcutaneous trigeminal nerve electrical neuromodulation</description>
    <arm_group_label>Cefaly Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients who have adequately understood the whole study procedures within age range of&#xD;
             19-64 years&#xD;
&#xD;
          2. Patients with insomnia severity index (ISI) score of more than 15&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Cognitive impairment&#xD;
&#xD;
          2. Psychiatric disorders or neurological disorders.&#xD;
&#xD;
          3. Unstable medical conditions&#xD;
&#xD;
          4. Prior diagnosis of sleep disorders&#xD;
&#xD;
          5. Hypnotic prescription&#xD;
&#xD;
          6. History of brain or facial trauma within 3 months&#xD;
&#xD;
          7. Skin abrasions&#xD;
&#xD;
          8. Acrylic acid allergy&#xD;
&#xD;
          9. Electromagnetic hypersensitivity&#xD;
&#xD;
         10. Apnea hypopnea index of &gt;15/hour in the baseline polysomnography.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Se-Min Choung</last_name>
    <role>Study Director</role>
    <affiliation>CMC IRB</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St.Vincent's Hospital, the Catholic University of Korea</name>
      <address>
        <city>Suwon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 4, 2021</study_first_submitted>
  <study_first_submitted_qc>April 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 8, 2021</study_first_posted>
  <last_update_submitted>April 6, 2021</last_update_submitted>
  <last_update_submitted_qc>April 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Saint Vincent's Hospital, Korea</investigator_affiliation>
    <investigator_full_name>Yoo Hyun Um</investigator_full_name>
    <investigator_title>Clinical Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Initiation and Maintenance Disorders</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 3, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/67/NCT04838067/SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

